After the release of the public comments for IVI-NSCLC, Managed Healthcare Executive took a look at IVI's open-source model focusing on non-small lung cancer and how it will bring healthcare executives insight into value that otherwise wouldn't exist with traditional models. Read the full article here.
In an article published on AJMC.com, IVI'sJennifer Bright discusses how IVI makes incorporating patients' perspectives a priority in developing open-source, transparent value models. Read the full article here.
PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression [...]